Semaglutide, oral — references and citing documents
The full reference list for this monograph, and every Institute document that draws on it.
§10References
Every reference the monograph relies on is listed below in order of first citation across the document. Identifiers are reproduced only where the Institute holds them; where a digital object identifier or PubMed identifier is not shown, the Institute has recorded the journal and year and has not constructed one.
This monograph cites 7 sources[1,2,3,4,5,6,7].
Table 9. Bibliographic records for the sources cited by this monograph. Each links to its record page, which lists every Institute document citing it.
| # | Title | Source | Year |
|---|---|---|---|
| 1 | Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes | New England Journal of Medicine | 2019 |
| 2 | PIONEER 1: randomized clinical trial of the efficacy and safety of oral semaglutide monotherapy in comparison… | Diabetes Care | 2019 |
| 3 | Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised… | The Lancet | 2023 |
| 4 | Oral semaglutide and cardiovascular outcomes in high-risk type 2 diabetes (SOUL): a randomised, double-blind… | New England Journal of Medicine | 2025 |
| 5 | Levels of circulating semaglutide determine reductions in HbA1c and body weight in people with type 2 diabetes | Cell Reports Medicine | 2021 |
| 6 | Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide | Journal of Medicinal Chemistry | 2015 |
| 7 | WEGOVY (semaglutide) injection, for subcutaneous use — Highlights of Prescribing Information | FDA Approved Labeling | 2024 |
§11Related Institute documents
Table 10. Institute documents that draw on, or are drawn on by, this monograph.
Numbered reference list
References are numbered in order of first citation in this document. Each superscript in the text links to its entry below.
- Husain M, Birkenfeld AL, Donsmark M, Dungan K, Eliaschewitz FG, Franco DR, Jeppesen OK, Lingvay I, Mosenzon O, Pedersen SD, Tack CJ, Thomsen M, Vilsbøll T, Warren ML, Bain SC. Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes. New England Journal of Medicine 2019;381(9):841–851. doi:10.1056/NEJMoa1901118 · PMID 31185157
- Aroda VR, Rosenstock J, Terauchi Y, Altuntas Y, Lalic NM, Morales Villegas EC, Jeppesen OK, Christiansen E, Hertz CL, Haluzík M. PIONEER 1: randomized clinical trial of the efficacy and safety of oral semaglutide monotherapy in comparison with placebo in patients with type 2 diabetes. Diabetes Care 2019;42(9):1724–1732. doi:10.2337/dc19-0749 · PMID 31186300
- Knop FK, Aroda VR, do Vale RD, Holst-Hansen T, Laursen PN, Rosenstock J, Rubino DM, Garvey WT. Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet 2023;402(10403):705–719. doi:10.1016/S0140-6736(23)01185-6 · PMID 37364590
- McGuire DK, Marso SP, Deanfield JE, Hovingh GK, Sattar N, Kahn SE, Hardt-Lindberg S, Rasmussen S, Ripa MS, Wolski K, Nissen SE, Lincoff AM. Oral semaglutide and cardiovascular outcomes in high-risk type 2 diabetes (SOUL): a randomised, double-blind, placebo-controlled trial. New England Journal of Medicine 2025;392(22):2001–2012. doi:10.1056/NEJMoa2501006
- Overgaard RV, Hertz CL, Ingwersen SH, Navarria A, Drucker DJ. Levels of circulating semaglutide determine reductions in HbA1c and body weight in people with type 2 diabetes. Cell Reports Medicine 2021;2(9):100387. doi:10.1016/j.xcrm.2021.100387 · PMID 34622226
- Lau J, Bloch P, Schäffer L, Pettersson I, Spetzler J, Kofoed J, Madsen K, Knudsen LB, McGuire J, Steensgaard DB, Strauss HM, Gram DX, Knudsen SM, Nielsen FS, Thygesen P, Reedtz-Runge S, Kruse T. Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide. Journal of Medicinal Chemistry 2015;58(18):7370–7380. doi:10.1021/acs.jmedchem.5b00726 · PMID 26308095
- United States Food and Drug Administration. WEGOVY (semaglutide) injection, for subcutaneous use — Highlights of Prescribing Information. FDA Approved Labeling 2024;Reference ID revision 01/2024. identifier not held by the Institute
Identifiers are reproduced only where the Institute holds them. Where a digital object identifier or PubMed identifier is not shown, the Institute has recorded the journal and year and has not constructed an identifier.